An Investigator Initiated, descriptive, proof-of-concept, open-label pilot study targeting the tumor microenvironment and skin barrier deficiency through JAK1/3 inhibition

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500599-79-00

Enrollment

Registered

2022-07-08

Start date

2023-01-10

Completion date

2025-08-06

Last updated

2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycosis Fungoides

Brief summary

• To evaluate complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and the overall response rate to treatment with Xeljanz.

Interventions

DRUGXELJANZ 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• To evaluate complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and the overall response rate to treatment with Xeljanz.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026